In our view, these structural and protein–ligand interaction data provide a basis of FAM72A protein ligand-binding sites, which require further investigation using well-defined in vitro and in vivo experiments to confirm the therapeutic activity of the suggested compound as potential leads for drug discovery screenings for the treatment of FAM72A-driven cancers (e.g., GBM and ACC) [185]. This evidence concerns the gene FAM72A and cancer.